Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i> -mutated non–small cell lung cancerEri Sugiyama, Hiroyoshi Nishikawa, Yoshiko Takeuchi et al.|Science Immunology|2020Cited by 285
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironmentYasuko Tada, Kohei Shitara|Journal for ImmunoTherapy of Cancer|2018Cited by 214